The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance

With sunitinib treatment of metastatic renal cell carcinoma, most patients end up developing resistance over time. Recent clinical trials have shown that individualizing treatment protocols could delay resistance and result in better outcomes. We developed an in vivo xenograft tumor model and compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Harrison Sicheng, Ding, Qiang, Lichner, Zsuzsanna, Kim, Sung Sun, Saleeb, Rola, Farag, Mina, Di Meo, Ashley, Plant, Pamela, Kaldas, Mirit, Bjarnason, Georg Arnold, Yousef, George Makram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779527/
https://www.ncbi.nlm.nih.gov/pubmed/35054064
http://dx.doi.org/10.3390/jcm11020369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779527/
https://www.ncbi.nlm.nih.gov/pubmed/35054064
http://dx.doi.org/10.3390/jcm11020369

Ejemplares similares